Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 3 institutions in 2 countries.
Masaw AkbariDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.ORCID 0000-0002-3257-5883
Jonathan D WestDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.
Nicholas DoerrDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.ORCID 0000-0001-9770-1206
Kevin R KippDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.
Neda MarhamatiDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.ORCID 0000-0002-8845-743X
Sabrina VuongDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.ORCID 0000-0001-8441-6131
Yidi WangDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.
Markus M RinschenDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50931 Cologne, Germany.
Jeffrey J TalbotDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.ORCID 0000-0003-2399-4610
Oliver WesselyDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195.
Thomas WeimbsDepartment of Molecular, Cellular, and Developmental Biology; and Neuroscience Research Institute, University of California, Santa Barbara, CA 93106-9625.ORCID 0000-0001-9423-5561
University of California, Santa Barbara · USCleveland Clinic Lerner College of Medicine · USUniversity of Cologne · DE
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Ketosis as a therapy for polycystic kidney diseaseR01DK124895 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI WEIMBS, THOMAS · 2020 to 2024
$2.2M
Regulation of the mTOR pathway in polycystic kidney diseaseR01DK078043 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI WEIMBS, THOMAS · 2007 to 2011
$1.4M
Role of renal crystal deposition in the progression of polycystic kidney diseaseR01DK109563 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI WEIMBS, THOMAS · 2017 to 2020
Autosomal dominant polycystic kidney disease (ADPKD) affects more than 500,000 individuals in the United States alone. In most cases, ADPKD is caused by a loss-of-function mutation in the
Indexed as
Fingolimod HydrochloridePolycystic Kidney, Autosomal DominantProtein Kinase CAnimalsDisease Models, AnimalDisease ProgressionEnzyme ActivationHumansMiceProtein Kinase C zetaTRPP Cation ChannelsFingolimod HydrochlorideProtein Kinase CProtein Kinase C zetaTRPP Cation Channelspolycystic kidney diseasepolycystin-1protein kinase C ζ
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progression. · full record | OpenQuestion